Poster OCT-598, a novel EP2/EP4 dual antagonist, promotes anti-tumor immune response in syngeneic mouse tumor models in combination with standard-of-care chemo- and immunotherapies
페이지 정보
작성자 DAAN
조회 444회 작성일 24-02-16 10:42
조회 444회 작성일 24-02-16 10:42
본문
| Journal | AACR |
|---|---|
| Name | 이영래, 백수정, 김동권 |
| Year | 2023 |
첨부파일
-
2023-AACR-Poster-EP24.pdf (1.5M)
0회 다운로드 | DATE : 2024-02-16 10:42:02
- 이전글Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma 24.02.20
- 다음글A novel AhR inhibitor ‘DA-4505’ enhanced the anti-cancer efficacy in combination with surgery, chemotherapy and pembrolizumab through increasing cytotoxic effects with antigen presentation 23.04.18